Neuraxis, INC — fact timeline

Neuraxis, INC shareholders approved Approval of Neuraxis, Inc. 2025 Employee Stock Purchase Plan at the 2026-06-10 meeting.

“4. The proposal regarding the Neuraxis, Inc. 2025 Employee Stock Purchase Plan was approved as follows:”

Neuraxis, INC shareholders approved Amendment to Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan at the 2026-06-10 meeting.

“3. The proposal regarding the amendment to Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan was approved as follows:”

Neuraxis, INC shareholders approved Ratification of appointment of Rosenberg Rich Baker Berman, P.A. as independent registered public accounting firm at the 2026-06-10 meeting.

“2. The proposal to ratify the appointment of Rosenberg Rich Baker Berman, P.A. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved as follows:”

Neuraxis, INC shareholders approved Election of six nominees for director at the 2026-06-10 meeting.

“1. The six nominees for director were elected to serve a one-year term as follows:”

Neuraxis, INC reported the three months ended March 31, 2026 results: revenue approximately $1.6 million.

“On April 21, 2026, Neuraxis, Inc. (the “Company”), issued disclosure that, on a preliminary unaudited basis, the Company expects its cash and cash equivalents to be approximately $7.1 million as of March 31, 2026. The Company expects its net sales to be approximately $1.6 million for the three months ended March 31, 2026, as compared to approximately $0.9 million for the three months ended March 31, 2025.”

Dr. Gil Aharon was appointed as Director at Neuraxis, INC.

“the Board appointed Dr. Aharon to the Board, effective January 1, 2025.”

Neuraxis, INC: Filed Amendment No. 1 to Certificate of Designation of Series B Preferred Stock to increase authorized shares, extend dividend right, and amend voting rights (effective 2024-11-15).

“On November 15, 2024, the Company filed Amendment No. 1 to Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock (the " COD Amendment ") with the Secretary of State of the State of Delaware to (i) increase the authorized number of shares designated as "Series B Preferred Stock" from 4,000,000 to 5,000,000, (ii) extend the right to dividends at a rate of 8.5% per annum by 18 months, from June 30, 2025 to December 31, 2026, and (iii) amend the voting rights of the stockholders of the Series B Preferred Stock that each holder of Series B Preferred Stock shall be entitled to cast votes equal to the number of shares of Common Stock into which the shares of Series B Preferred Stock held by such holder are convertible on the basis of a conversion price of $3.80.”

Dan Clarence was terminated as Chief Operating Officer at Neuraxis, INC.

“On April 10, 2024, the employment of Dan Clarence, Chief Operating Officer of NeurAxis, Inc. (the "Company"), terminated effective immediately.”

Neuraxis, INC reported the year ended December 31, 2023 results: revenue $2.5 million.

“medical space well, I believe we are well positioned to execute our business plan in 2024. ” Fourth Quarter and Fiscal Year 2023 Financial Results Revenue in fiscal year 2023 of $2.5 million was down 8.4% compared to $2.7 million in fiscal year 2022. The decrease was primarily due to fewer shipments to certain customers as they manage th”

Neuraxis, INC reported that prior financial statements should not be relied upon.

“On April 4, 2024, the Board of Directors (the “Board”) of the Company, upon the recommendation of the Audit Committee of the Board and after discussion with management, concluded that the Company’s previously issued unaudited financial statements as of and for the three and nine months period ended September 30, 2023 filed with the Securities and Exchange Commission on November 20, 2023, should no longer be relied upon and should be restated due to the identification of a material accounting error.”

Neuraxis, INC amended SPA with Flagstaff International, LLC valued at $5 million (effective 2024-03-22).

“On March 22, 2024, the Company and Flagstaff entered into the third amendment to the SPA (the “Amendment”) to increase the investment amount from $3 million to $5 million”

Kristin Ferge was appointed as Director and Chairman of Audit Committee at Neuraxis, INC.

“On March 7, 2024, the Board of Directors (the “Board”) of NeurAxis, Inc. (the “Company”) appointed Kristin Ferge to the Board to serve until the Company’s next annual meeting of shareholders.”

Neuraxis, INC incurred convertible notes of $457,000 at 8.5% per annum maturing the earlier of (i) upon written demand of the Investors occurring on or after twelve (12) months from the date of the Notes in the event that the Series B Prefe.

“On each of February 9, 2024 and February 14, 2024, the Company entered into securities purchase agreements (the “SPAs”) with a total of two accredited investors (the “Investors”) for the issuance and purchase of convertible promissory notes (the “Notes”) for an aggregate purchase price of $457,000. The Notes bear an interest rate of 8.5% per annum, which shall be payable quarterly by the Company in cash or in shares of the Company’s common stock at the conversion price as defined in the form of the Certificate of Designation of the Series B Convertible Preferred Stock attached as an exhibit to the SPAs. The maturity date of the Notes shall be on the earlier of (i) upon written demand of the Investors occurring on or after twelve (12) months from the date of the Notes in the event that the Series B Preferred Stock has not been duly authorized or (ii) immediately upon the occurrence of an event of default.”

Neuraxis, INC entered into "SPAs" with a total of two accredited investors valued at $457,000 (effective 2024-02-09).

“On each of February 9, 2024 and February 14, 2024, the Company entered into securities purchase agreements (the "SPAs") with a total of two accredited investors (the "Investors") for the issuance and purchase of convertible promissory notes (the "Notes") for an aggregate purchase price of $457,000.”

Timothy R. Henrichs was appointed as Chief Financial Officer at Neuraxis, INC.

“On January 26, 2024, the Board appointed Mr. Henrichs to serve as the CFO (the “CFO Appointment”). Mr. Henrichs’s employment will begin on February 5, 2024”

Timothy R. Henrichs resigned as Director at Neuraxis, INC.

“on January 25, 2024, Timothy R. Henrichs resigned as a member of the Board of Directors (the “Board”) of NeurAxis, Inc. (the “Company”), effective February 2, 2024.”

John Seale resigned as Chief Financial Officer at Neuraxis, INC.

“on January 30, 2024, John Seale resigned as the Company’s Chief Financial Officer (the “CFO”) effective as of the close of business on January 30th.”

Neuraxis, INC entered into Registration Rights Agreement with Flagstaff International (effective 2023-11-09).

“In connection with the SPA, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Flagstaff International.”

Neuraxis, INC entered into SPA with Flagstaff International, LLC valued at $3,000,000 (effective 2023-11-09).

“On November 9, 2023, Neuraxis, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with Flagstaff International, LLC ( “Flagstaff International”) for the issuance and purchase of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”), at price per share of $2.38. The aggregate purchase price is $3,000,000”

Neuraxis, INC reported the second quarter ended June 30, 2023 results: revenue $646.0 thousand, net income ($2,235.6) thousand, EPS ($1.21) per common share.

“of care for children with abdominal pain related disorders of the gut-brain interactions.” 1 Second Quarter 2023 Financial Results Revenue for the second quarter of 2023 was $646.0 thousand, representing a decrease of 5% compared to $682.6 thousand in the second quarter of 2022. The decrease was primarily due to ordering patterns of our major customers. Gross profit”

Neuraxis, INC entered into Underwriting Agreement with Alexander Capital, L.P. (effective 2023-08-08).

“we entered into an Underwriting Agreement (“Underwriting Agreement”), dated August 8, 2023, with Alexander Capital, L.P. as representative of the underwriters named therein.”